Publications by authors named "Giuseppe Ando"

Background: The tricuspid valve (TV) is a complex three-dimensional (3D) anatomical structure; however, current guidelines recommend tricuspid annulus (TA) measurements to be performed with two-dimensional (2D) echocardiography. The aim of this study was to compare TV measurements obtained with 2D and four-dimensional (4D) echocardiography for surgical planning.

Methods: All echocardiographic data of patients referred to our center for TV assessment were collected.

View Article and Find Full Text PDF

Drug-coated balloons (DCBs) have emerged as a promising alternative therapeutic strategy to traditional drug-eluting stent (DES) implantation in various coronary artery lesion scenarios, aiming to minimize complications associated with permanent metallic scaffolds, such as chronic inflammation, delayed vessel healing, and stent thrombosis. This review systematically evaluates the current clinical evidence supporting the use of DCBs across diverse anatomical and clinical contexts, including small-vessel disease, in-stent restenosis, bifurcation lesions, diffuse coronary lesions, acute coronary syndromes, and chronic total occlusions, as well as in special patient populations such as individuals with diabetes mellitus or at high bleeding risk. The literature analysis incorporated recent randomized controlled trials, observational studies, and real-world registries, highlighting the clinical efficacy, safety profiles, and specific advantages of DCB angioplasty.

View Article and Find Full Text PDF

Chronic inflammation is a pivotal driver in the progression of atherosclerosis, significantly contributing to the burden of cardiovascular disease (CVD). Patients with chronic inflammatory diseases, such as inflammatory bowel diseases (IBDs) (e.g.

View Article and Find Full Text PDF

Background: Acute coronary syndrome triggered by hypersensitivity to various natural, chemical, or pharmaceutical allergens is known as Kounis syndrome. Kounis syndrome is classified in three subtypes based on its pathophysiological mechanism and outcome. Among pharmaceuticals, cephalosporins are frequently implicated in allergic illnesses, with ceftriaxone being one of the most frequently reported causes.

View Article and Find Full Text PDF

Introduction: Monoclonal antibodies (mAbs) have revolutionized the treatment of multiple myeloma (MM), demonstrating remarkable effectiveness, despite potential adverse events (AEs). This study aims to identify unexpected signals of disproportionate reporting (SDRs) for cardiovascular (CV) and respiratory AEs associated with mAbs in MM treatment.

Methods: From January 2015 to December 2023, reports involving suspected drugs (daratumumab, elotuzumab, elranatamab, isatuximab, belantamab mafodotin, teclistamab, and talquetamab) were analyzed in the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

View Article and Find Full Text PDF

Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor, is the standard treatment for patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES). However, the optimal duration of DAPT remains debated due to the need to balance ischemic event reduction with bleeding risks. This study evaluates the efficacy and safety of ticagrelor monotherapy after short-duration DAPT (1 to 3 months) compared to extended DAPT, focusing on major bleeding and cardiovascular outcomes.

View Article and Find Full Text PDF

Background: The prospective, single-arm, observational, phase 4 ETNA-AF Europe study collected real-world data about safety, effectiveness and therapeutic adherence in European patients with non-valvular atrial fibrillation newly prescribed with edoxaban and followed up for 4 years.

Methods: Overall, 13 164 patients were included in the full-analysis set, which means that they had at least one documentation after baseline at 4 years. The current paper reports about the 3329 Italian patients out of the whole European population.

View Article and Find Full Text PDF
Article Synopsis
  • Acute coronary syndromes (ACS) represent a major challenge in cardiovascular healthcare, even with improvements in treatment and understanding in recent years.
  • ACS includes a range of conditions related to sudden, reduced blood flow to the heart, leading to serious health complications.
  • Ongoing research and development are crucial for further advancements in diagnosing and managing these conditions effectively.
View Article and Find Full Text PDF

In acute myocardial infarction (AMI), the urgency of coronary revascularization through percutaneous coronary intervention (PCI) is paramount, offering notable advantages over pharmacologic treatment. However, the persistent risk of adverse events, including recurrent AMI and heart failure post-revascularization, underscores the necessity for enhanced strategies in managing coronary artery disease. Traditional angiography, while widely employed, presents significant limitations by providing only two-dimensional representations of complex three-dimensional vascular structures, hampering the accurate assessment of plaque characteristics and stenosis severity.

View Article and Find Full Text PDF
Article Synopsis
  • * Treatment for obstructive CAD focuses on reducing heart events and symptoms, while INOCA requires addressing functional changes in coronary circulation.
  • * A precise diagnosis in patients with INOCA is vital for personalized treatment, and the paper emphasizes combining coronary revascularization, medication, and lifestyle changes for effective angina management.
View Article and Find Full Text PDF
Article Synopsis
  • Primary percutaneous coronary intervention (PCI) is the preferred method for treating acute ST-elevation myocardial infarction (STEMI), helping to restore blood flow in blocked arteries.
  • Some patients, however, suffer from a 'no-reflow' phenomenon, where blood flow remains compromised despite the artery being opened, usually due to microvascular obstruction from thrombus or plaque.
  • There is no clear consensus on preventing or treating no-reflow, and while various medications are used, they only improve blood flow for certain patients; a new idea involving low-dose fibrinolysis during PCI shows promise for enhancing recovery.
View Article and Find Full Text PDF
Article Synopsis
  • International guidelines recommend using direct oral anticoagulants (DOAC) over vitamin K antagonists (VKA) and dual antithrombotic therapy (DAT) over triple antithrombotic therapy (TAT) for patients on oral anticoagulant therapy undergoing percutaneous coronary intervention (PCI) with stents.
  • A study involving 1234 patients on oral anticoagulants assessed the outcomes of DOAC versus VKA and DAT versus TAT, focusing on net adverse clinical events (NACE) at a one-year follow-up.
  • Results showed DOAC resulted in a lower NACE rate compared to VKA (16% vs 23%), and while DAT and TAT had similar NACE rates, DAT led to
View Article and Find Full Text PDF
Article Synopsis
  • * It can be linked to conditions like subvalvar aortic stenosis, bicuspid aortic valve, or aortic coarctation.
  • * Using various imaging techniques is crucial for evaluating the mitral apparatus properly.
View Article and Find Full Text PDF

Background: The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) enrolled 1445 older (aged ≥75 years) patients with myocardial infarction and multivessel disease in Italy, Spain, and Poland. Patients were randomized to physiology-guided complete revascularization or treatment of the only culprit lesion. Physiology-guided complete revascularization significantly reduced ischemic adverse events at 1 year.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the "smoker's paradox," where smoking patients with ST segment elevation myocardial infarction (STEMI) appear to have better outcomes compared to non-smokers after treatment.
  • Out of 2,546 STEMI patients, 1,007 (41%) were current smokers, who were generally younger and experienced significantly lower in-hospital and 1-year mortality rates.
  • The findings suggest that while younger age may partly explain the better outcomes for smokers, smoking habits still independently contribute to reduced mortality after percutaneous coronary intervention (PCI).
View Article and Find Full Text PDF
Article Synopsis
  • This study examines the impact of starting PCSK9 inhibitors (PCSK9i) at the time of hospitalization for acute coronary syndrome (ACS) on lipid levels and cardiovascular (CV) events in a real-world setting.
  • It analyzed data from 771 ACS patients, revealing that a significant 68.3% achieved the target LDL-C of < 55 mg/dL within a median of 37 days after hospitalization.
  • Results showed that lower LDL-C levels were associated with reduced risks of major cardiovascular events, suggesting that early and aggressive lipid management with PCSK9i is both safe and beneficial for ACS patients.
View Article and Find Full Text PDF
Article Synopsis
  • Patients with high bleeding risk (HBR) following a myocardial infarction (MI) face poor outcomes, and it's uncertain if they benefit from complete revascularization.
  • The study aimed to compare the outcomes of physiology-guided complete revascularization versus a culprit-only strategy for HBR patients with MI and multivessel disease.
  • Results showed that HBR patients had a higher risk of complications, but those who underwent complete revascularization experienced significantly better outcomes, reducing primary endpoint events.
View Article and Find Full Text PDF
Article Synopsis
  • Acute coronary syndromes (ACS) include serious heart conditions like STEMI and NSTE-ACS, posing significant challenges in treatment due to their complex nature and impacts on health.
  • The 2023 European Society of Cardiology (ESC) guidelines for managing ACS highlight updates in treatment timing, patient assessment strategies, and various advanced imaging techniques to improve diagnostic accuracy.
  • These guidelines also suggest personalized approaches in antiplatelet therapy and introduce low-dose colchicine, while noting that there are still areas for improvement in adopting personalized care and technology in ACS management.
View Article and Find Full Text PDF